Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

Published:2018-04 Issue:S2 Volume:7 Page:S91-S94
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl. Lung Cancer Res.

Author:

Salati Massimiliano,Baldessari Cinzia,Cerbelli Bruna,Botticelli Andrea

Publisher

AME Publishing Company

Subject

Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy;eLife;2022-09-20

2. Signal pathways and precision therapy of small-cell lung cancer;Signal Transduction and Targeted Therapy;2022-06-15

3. Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis;Frontiers in Immunology;2021-08-09

4. A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab;Cancer Medicine;2021-07-31

5. Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question;Clinical and Translational Oncology;2021-02-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP